MetAP2 inhibitors have emerged as a significant class of compounds targeting a variety of diseases, including cancer, angiogenesis-related conditions, immune modulation, inflammation, and metabolic disorders such as obesity and T2DM. Here, METAP2 is linked to obesity due to melanocortin 4 receptor deficiency.